潜江永安药业股份有限公司关于控股股东、实际控制人及其一致行动人权益变动触及5%整数倍的提示性公告

Group 1 - The core point of the announcement is that the controlling shareholder, Huanggang Yong'an Pharmaceutical Co., Ltd., plans to reduce its shareholding in the company by up to 2,632,300 shares, which is approximately 0.8933% of the total share capital [1] - As of September 4, 2025, Huanggang Yong'an has already reduced its holdings by 410,000 shares, representing 0.1391% of the total share capital, bringing the total shares held by the controlling shareholder and its concerted actors to 73,587,232 shares, or 24.9717% of the total share capital [2] Group 2 - The company has approved the use of up to RMB 750 million of its own funds for entrusted wealth management, with a validity period of no more than 12 months [3] - On September 5, 2025, the wholly-owned subsidiary, Wuhan Yaan Investment Management Co., Ltd., invested RMB 16 million in a wealth management product from Guotai Haitong Securities, with an expected annualized return of 3.5% plus excess returns [4][5] - The company has also made several other investments in wealth management products, including a RMB 34 million investment in a product from China Zhongjin Wealth Securities with an expected return of 2.5%-3.5% [6][7] - As of the announcement date, the total amount of wealth management products purchased using idle funds is approximately RMB 61,240 million, accounting for 30.72% of the most recent audited net assets [24]